The estimated Net Worth of Uday Kompella is at least 8.5 百万$ dollars as of 1 November 2021. Dr Kompella owns over 50,000 units of Ocugen Inc stock worth over 189,932$ and over the last 5 years he sold OCGN stock worth over 8,265,851$. In addition, he makes 44,765$ as Co-founder & Independent Director at Ocugen Inc.
Dr has made over 9 trades of the Ocugen Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 50,000 units of OCGN stock worth 751,500$ on 1 November 2021.
The largest trade he's ever made was selling 350,000 units of Ocugen Inc stock on 26 April 2021 worth over 4,095,000$. On average, Dr trades about 51,479 units every 13 days since 2020. As of 1 November 2021 he still owns at least 154,416 units of Ocugen Inc stock.
You can see the complete history of Dr Kompella stock trades at the bottom of the page.
Dr. Uday B. Kompella Ph.D. is the Co-founder & Independent Director at Ocugen Inc.
As the Co-founder & Independent Director of Ocugen Inc, the total compensation of Dr D at Ocugen Inc is 44,765$. There are 4 executives at Ocugen Inc getting paid more, with Dr. Shankar Musunuri M.B.A., MBA, Ph.D. having the highest compensation of 780,673$.
Dr D is 54, he's been the Co-founder & Independent Director of Ocugen Inc since . There are 9 older and 7 younger executives at Ocugen Inc. The oldest executive at Ocugen Inc is Prabhavathi Fernandes, 71, who is the Independent Director.
Uday's mailing address filed with the SEC is C/O OCUGEN, INC., 11 GREAT VALLEY PARKWAY, MALVERN, PA, 19355.
Over the last 5 years, insiders at Ocugen Inc have traded over 18,069,176$ worth of Ocugen Inc stock and bought 1,511,356 units worth 684,830$ . The most active insiders traders include Shankar Musunuri、Junge Zhang、Uday Kompella. On average, Ocugen Inc executives and independent directors trade stock every 21 days with the average trade being worth of 96,347$. The most recent stock trade was executed by Junge Zhang on 14 June 2023, trading 200,278 units of OCGN stock currently worth 100,139$.
ocugen, inc., is a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved ocular disorders. the company’s lead programs in ocular graft versus host disease (ocu300) and chronic dry eye disease (ocu310) are expected to enter pivotal clinical trials in 2018. ocu300 received the first and only orphan drug designation for ocular graft versus host disease, providing certain regulatory and economic benefits. ocugen is also developing novel biologic therapies for retinitis pigmentosa (ocu100) and wet amd (ocu200), as well as a groundbreaking modifier gene therapy platform with potential to address a broad spectrum of inherited retinal disorders (ocu400). for more information, please visit www.ocugen.com.
Ocugen Inc executives and other stock owners filed with the SEC include: